<?xml version="1.0" encoding="UTF-8"?>
<ref id="B27-molecules-25-03830">
 <label>27.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gul</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ozcan</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Asar</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Okyar</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Baris</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Kavakli</surname>
    <given-names>I.H.</given-names>
   </name>
  </person-group>
  <article-title>
   <italic>In Silico</italic> Identification of Widely Used and Well Tolerated Drugs That May Inhibit SARSCov-2 3C-like Protease and Viral RNA-Dependent RNA Polymerase Activities, and May Have Potential to Be Directly Used in Clinical Trials
  </article-title>
  <source>ChemRxiv</source>
  <year>2020</year>
  <comment>PPR: PPR151426</comment>
  <pub-id pub-id-type="doi">10.26434/chemrxiv.12123204.v1</pub-id>
 </element-citation>
</ref>
